Zantac / Ranitidine (NDMA Cancer) Attorney in Chicago, Illinois

Zantac Litigation in Chicago / Cook County

Chicago's Cook County Circuit Court has extensive experience with pharmaceutical mass tort litigation and complex civil cases. Illinois applies Daubert under IL R. Evid. 702 — the same framework that closed the federal MDL — making causation expert challenges in Illinois similar to those in federal court. However, the Delaware Superior Court under Judge Medinilla has demonstrated a more favorable approach to Zantac causation experts. Chicago-area Zantac claimants should consult experienced plaintiffs' counsel about whether to file in Cook County Circuit Court or coordinate in Delaware. The federal Zantac MDL (No. 2924, S.D. Florida) was largely dismissed in 2022 after Judge Robin Rosenberg excluded plaintiffs' causation experts under Daubert. However, the Delaware Superior Court under Judge Vivian Medinilla continues to actively hear Zantac cases and has allowed causation experts to proceed. Defendants Sanofi, Boehringer Ingelheim, GSK, and Pfizer are all actively litigating in Delaware. For most claimants, filing in Delaware Superior Court through national plaintiffs' counsel is now the primary path forward.

Resources for Chicago Zantac Cancer Claimants

Chicago-area Zantac claimants with bladder, esophageal, stomach, or colorectal cancer diagnoses linked to documented ranitidine use should gather pharmacy records from Walgreens (headquartered in Chicago), CVS, and independent pharmacies. Illinois's 2-year SOL with the discovery rule means claimants with 2024 diagnoses have an active window; earlier diagnoses require discovery rule analysis. Multiple Chicago-area plaintiffs' firms participate in national Zantac litigation coordination.